Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AGEN with free AI briefings, catalyst countdowns, and dilution alerts.

AGEN · Agenus Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$86.9M Cash on Hand
10.2mo Cash Runway
Follow AGEN by email Get an email when AGEN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AGEN, unsubscribe in one click. Privacy

📣 What AGEN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Balstilimab (AGEN2034) Resectable MMR-deficient Solid Tumors Phase 2/3 · NCT06279130 Recruiting
Folfox Protocol Gastric Cancer Phase 3 · NCT06346197 Recruiting
Irinotecan Advanced Cancer Phase 3 · NCT04943627 Withdrawn
Botensilimab Resectable MMR-deficient Solid Tumors Phase 2/3 · NCT06279130 Recruiting
XELOX Gastric Cancer Phase 3 · NCT06346197 Recruiting
GVAX Pancreatic Cancer Phase 1/2 · NCT06782932 Recruiting
QS21 Herpes Simplex Type 2 Phase 2 · NCT01687595 Completed
Vitespen (HSPPC-96) Recurrent Glioblastoma Phase 2 · NCT01814813 Terminated
Doxorubicin Hydrochloride Newly Diagnosed Glioblastoma Phase 2 · NCT05864534 Active not recruiting
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Pancreatic Cancer Phase 1/2 · NCT06782932 Recruiting
Zalifrelimab (AGEN1884) Pancreatic Ductal Adenocarcinoma Phase 1/2 · NCT04827953 Active not recruiting
Nab-paclitaxel Pancreatic Ductal Adenocarcinoma Phase 1/2 · NCT04827953 Active not recruiting
Hedgehog Inhibitor NLM-001 Pancreatic Ductal Adenocarcinoma Phase 1/2 · NCT04827953 Active not recruiting
Anti-CD137 Agonistic Monoclonal Antibody… Pancreatic Cancer Phase 1/2 · NCT06782932 Recruiting
autologous human tumor-derived HSPPC-96 Lymphoma, Follicular Phase 2 · NCT00081809 Completed
Balstilmab Anatomic Stage IV Breast Cancer AJCC v8 Phase 1/2 · NCT05318469 Recruiting

Also used in these trials (approved or third-party drugs, not AGEN's own candidates): Leucovorin, Gemcitabine Hydrochloride, Nivolumab, Vinorelbine, Topotecan, Pemetrexed Disodium, Ipilimumab, Ivermectin, Oxaliplatin, Pembrolizumab, Panitumumab, GM-CSF-encoding Oncolytic Adenovirus CGTG-102.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AGEN holds $86.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $25.6M/quarter from operations, an estimated runway of 10.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 59 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AGEN files for a raise →

👥 Who Owns AGEN

Insiders 1% Other 5%+ holders 25.7% Institutions (168 holders) 50.5% Public and other holders 22.8%
HolderTypeShares% of sharesAs of
TCG Crossover GP III, LLC 5%+ holder (13G) 4,954,779 10.95% 2026-09-30
Raymond Debbane 5%+ holder (13G) 4,533,755 10.02% 2026-07-13
RA Capital Management, L.P. Institution (13G, 5%+) 4,344,772 9.60% 2026-07-13
BlackRock, Inc. Institution (13G, 5%+) 2,513,893 5.56% 2026-06-30
Eventide Asset Management, LLC Institution (13G, 5%+) 2,446,789 5.41% 2026-09-30
ZYNEXT VENTURES USA LLC 5%+ holder (13D) 2,133,333 4.71% 2026-01-15
Garo H Armen
Chairman, Chief Executive Officer and Pr · +2.11M options
Insider 400,058 0.88% 2026-07-10
Thomas L Harrison
Director · +172,500 options
Insider 51,988 0.11% 2026-10-01
Austin Charette
Principal Accounting Officer · +17,619 options
Insider 9,115 0.02% 2026-01-08
Marco Tullio Marcucci
Director · +7,500 options
Insider 5,480 0.01% 2026-08-05

Share count 45,246,510 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AGEN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AGEN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.